Riverain Technologies develops medical software intended to improve the detection, characterization, and management of lung cancers and other lung diseases. The company's software leverages patented image normalization and suppression technology to achieve robust solutions that generalize across different manufacturers devices and imaging protocols. The patented suppression technology improves the detection of lung diseases and other clinical conditions via bone-suppressed X-ray images and vessel-suppressed CT series that remove challenging structures, making disease more visible and easier to identify.
Riverain Technologies is a seasoned player in the medical AI space. The company was the first ever to receive FDA approval for a CAD software device for concurrent use and all-nodule-type detection. The company’s products are CE marked and FDA approved, and are used at hundreds of sites worldwide.